IRCT20120215009014N486
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin as adjunctive therapy versus placebo on serum level of oxidative stress biomarkers in non-diabetic patients with systolic heart failure: a double-blind randomized clinical trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hamedan University of Medical Sciences
- Enrollment
- 80
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 to 80 years
- •Controlled systolic heart failure for at least 6 months
- •Hemoglobin A1c less than 6\.5
- •Stable clinical and hemodynamic status
Exclusion Criteria
- •Pregnancy or breastfeeding
- •Inflammatory, respiratory, infectious or malignant diseases
- •History of myocardial infarction, stroke, angioplasty or CABG in the last 3 months
- •Embedding pacemaker in the last 3 months
- •Use of anti\-oxidant or anti\-inflammatory drugs or corticosteroids in the last 3 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Effect of Empagliflozin as adjunctive therapy versus placebo on serum level of oxidative stress biomarkers in diabetic patients with systolic heart failureIRCT20120215009014N484Hamedan University of Medical Sciences80
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Completed
N/A
Evaluation of the effect of empagliflozin in combination with pioglitazone on fatty liver diseaseFatty liver.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20240208060939N1Artesh University of Medical Sciences80
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
Recruiting
Phase 2
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgeryAtrial fibrillation after heart surgery.Paroxysmal atrial fibrillationIRCT20120520009801N9Mashhad University of Medical Sciences160